U.S. markets close in 3 hours 2 minutes
  • S&P 500

    4,406.33
    +38.85 (+0.89%)
     
  • Dow 30

    35,025.35
    +202.00 (+0.58%)
     
  • Nasdaq

    14,814.24
    +129.65 (+0.88%)
     
  • Russell 2000

    2,198.83
    -0.65 (-0.03%)
     
  • Crude Oil

    71.98
    +0.07 (+0.10%)
     
  • Gold

    1,802.70
    -2.70 (-0.15%)
     
  • Silver

    25.29
    -0.09 (-0.36%)
     
  • EUR/USD

    1.1774
    +0.0001 (+0.01%)
     
  • 10-Yr Bond

    1.2850
    +0.0200 (+1.58%)
     
  • GBP/USD

    1.3757
    -0.0010 (-0.07%)
     
  • USD/JPY

    110.5370
    +0.4220 (+0.38%)
     
  • BTC-USD

    32,199.30
    -131.54 (-0.41%)
     
  • CMC Crypto 200

    778.66
    -15.07 (-1.90%)
     
  • FTSE 100

    7,027.58
    +59.28 (+0.85%)
     
  • Nikkei 225

    27,548.00
    +159.80 (+0.58%)
     

Merck/Eisai's Keytruda-Lenvima Combo Results in Better Health-Related Quality of Life Measures Compared to Sunitinib

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Merck & Co Inc (NYSE: MRK) has announced new data from Phase 3 CLEAR (Study 307)/KEYNOTE-581 trial, which evaluated the combinations of Keytruda (pembrolizumab) plus Lenvima from Eisai Co Ltd (OTC: ESALY), and Lenvima plus everolimus versus Pfizer Inc’s (NYSE: PFE) Sutent (sunitinib) in renal cell carcinoma (RCC).

  • Results from a new analysis evaluating health-related quality of life (HRQoL) based on patient-reported outcomes are being presented during an oral abstract session.

  • Data were presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.

  • In an analysis of a secondary endpoint of Health‐Related Quality of Life (HRQoL), scores were assessed.

  • Keytruda + Lenvima demonstrated similar changes from baseline at mean follow-up (Week 46) on 14 out of 18 HRQoL and disease-related symptom scores and better HRQoL and disease-related symptom scores for various measures including physical functioning, fatigue, dyspnea, and constipation, versus sunitinib.

  • As reported earlier, the keytruda-lenvima combo showed significant extension in the time patients lived without their disease getting worse in a head-to-head matchup with sunitinib, the standard of care.

  • Price Action: MRK shares are down 0.43% at $73.79 during the market session on the last check Monday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.